Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
European advisory group backs Merck's HIV meds Delstrigo and Pifeltro

The European Medicines Agency's advisory group CHMP adopts a positive opinion backing approval for Merck's (NYSE:MRK) DELSTRIGO (doravirine, lamivudine and tenofovir disoproxil fumarate) and PIFELTRO (doravirine) for the treatment of adults with chronic HIV-1 infection.

Published
13 hours ago
From
Seeking Alpha
PrEP drug patent overturned in UK - NAT respond

The High Court has today overturned Gilead's patent extension on Truvada, the HIV drug also used in PrEP.

Published
18 September 2018
From
National AIDS Trust
A Crazy, Murky System for Pricing HIV Drugs

A new gold-standard triple therapy for H.I.V. has just made its debut in Africa. It costs $75 a year. In the United States, many people with H.I.V. take an almost identical therapy. It costs $39,000 a year. The United States is infamous for its high cost of health care — and HIV medicines are a big part of that.

Published
18 September 2018
From
New York Times
EPO Upholds Gilead Patent On Hep C Medicines, But In Amended Form

The European Patent Office (EPO) on 13 September ruled in favour of pharmaceutical company Gilead and maintained the company’s patent on hepatitis C drug sofosbuvir. The patent, however, is maintained in an amended form. Civil society involved in the case expressed dismay over the outcome and its potential effect on European drug prices.

Published
16 September 2018
From
Intellectual Property Watch
Groups Call for End to Gilead’s Unwarranted Hepatitis C Drug Monopoly in Europe

This week in Munich, the European Patent Office (EPO) will hear a legal challenge filed by groups in 17 countries against an unmerited patent that allows US-based pharmaceutical corporation Gilead Sciences to charge exorbitant prices in Europe for the key hepatitis C drug sofosbuvir.

Published
11 September 2018
From
MSF press release
CJEU Ruling on Truvada recalls ‘evergreening’ goes against public health interests

On 25th July 2018, the Court of Justice of the European Union (CJEU) rendered its preliminary ruling on the interpretation of Article 3(a) of Regulation (EC) No 469/2009 concerning the supplementary protection certificate (SPC) for medicinal products.

Published
10 September 2018
From
Medicines Law & Policy
Chasing top HIV players, Merck scores FDA approval for 2 new drugs

After marquee HIV drug approvals last year for Gilead and GlaxoSmithKline, Merck will follow into the crowded market with two new meds. The drugmaker scored FDA approvals for a new non-nucleoside reverse transcriptase inhibitor called doravirine, both alone and in a combo with other HIV therapies.

Published
01 September 2018
From
FiercePharma
Should Gilead Be Worried About This New Monthly HIV Medication?

Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

Published
16 August 2018
From
Motley Fool
Gilead Said PrEP To Prevent HIV Was 'Not A Commercial Opportunity.' Now It's Running Ads For It

The commercial, aptly titled "I'm on the Pill," is part of a marketing push that has helped turned the use of Truvada for preventing HIV into a $1.3 billion blockbuster, almost 5% of Gilead's annual sales.

Published
07 August 2018
From
Forbes Magazine
Mylan, lambasted for EpiPen price hikes, complains of overpriced anti-HIV drugs in the United States

Mylan, a giant generic drugmaker headquartered in Canonsburg, Pennsylvania, that took a bashing in 2016 for steeply raising the price of its EpiPen that treats severe allergic reactions, has now flipped the tables and is arguing that the United States is wasting billions of dollars on name brand anti-HIV drugs instead of its cheaper alternatives.

Published
07 August 2018
From
Science
← First12345...107Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.